<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02856542</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-DAIVOBETGEL-1284</org_study_id>
    <nct_id>NCT02856542</nct_id>
  </id_info>
  <brief_title>Real-life Evaluation of the Daivobet® Gel Applicator</brief_title>
  <acronym>ASAP PSO</acronym>
  <official_title>Real-life Evaluation of an Applicator, as a New Mode of Administration of Daivobet® Gel, on Adherence to Treatment and SAtisfaction of Patients With PSOriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to describe the patient population being treated and evaluate their treatment
      adherence and treatment outcomes during treatment of scalp psoriasis with Daivobet® gel
      Applicator for 4 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 23, 2016</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Morisky Medication Adherence Scale-8</measure>
    <time_frame>2 weeks</time_frame>
    <description>Degree of adherence to prescribed treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Morisky Medication Adherence Scale-8</measure>
    <time_frame>4 weeks</time_frame>
    <description>Degree of adherence to prescribed treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient opinion on Applicator usability</measure>
    <time_frame>4 weeks</time_frame>
    <description>5-point Likert scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient overall satisfaction</measure>
    <time_frame>4 weeks</time_frame>
    <description>4 point Likert scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Improvement</measure>
    <time_frame>2 weeks</time_frame>
    <description>7 point Likert scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Improvement</measure>
    <time_frame>4 weeks</time_frame>
    <description>7 point Likert scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator's opinion on the properties of the Applicator</measure>
    <time_frame>Baseline</time_frame>
    <description>5 point rating scale</description>
  </secondary_outcome>
  <enrollment type="Actual">1560</enrollment>
  <condition>Plaque Psoriasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>calcipotriol/betamethasone dipropionate gel in Applicator</intervention_name>
    <description>Topical treatment of scalp using applicator device. The study as such is non-interventional as the intervention has been decided prior to and independently from the inclusion of the patient in the cohort to be observed.</description>
    <other_name>Daivobet® gel Applicator</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with psoriasis vulgaris affecting the scalp who are prescribed scalp
        treatment with Daivobet® gel Applicator.

        Representativeness is ensured through random sampling of investigators to be invited to
        participate from a country wide list of dermatologists and general practitioners, with
        adjustment for regional distribution. Investigators include their first three patients
        meeting the study criteria.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Dermatologist or general practitioner has decided to initiate treatment with Daivobet®
             gel Applicator

        Exclusion Criteria:

          -  Indication not within the approved labelling in France

          -  Contraindication for treatment with calcipotriol or betamethasone dipropionate

          -  Informed consent to participate in the study has not been obtained
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathilde Kemula, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cabinet de Dermatologie, Dr. Mathilde Kemula</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frederic Bonnier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Practice, 356 Rue de Charles de Gaulle, 91400 Orsay</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nathalie Quiles, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Saint Joseph, 26 Boulevard de Louvain, Marseille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cabinet de Dermatologie, Dr. Mathilde Kemula</name>
      <address>
        <city>Charenton le Pont</city>
        <zip>94220</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986 Jan;24(1):67-74.</citation>
    <PMID>3945130</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2016</study_first_submitted>
  <study_first_submitted_qc>August 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2016</study_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis vulgaris, scalp, topical, applicator, device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

